Thomas Martin is a Gastroenterology physician. ClinicalTrials.gov lists 18 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1378 NW 124th St
Suite 200
Clive, IA 503258151
Telephone
515-288-6097Registry record last updated 6 May 2015.
Clinical trials
- Rapid-infusion Isatuximab in Relapsed/Refractory Multiple Myeloma
Sponsor: Thomas Martin, MD
- COVID-19 and Anti-CD14 Treatment Trial
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
25 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year202512 payments
- DePuy Synthes Sales Inc.Program year20251 payment
- LUMENDI LLCProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
93%Proton pump inhibitor48.3%Pantoprazole Sodium74%Omeprazole20%Dexlansoprazole Dr4%Lansoprazole2%Part D<11 patientsSerotonin-3 Receptor Antagonist16.6%Ondansetron Hcl61%Ondansetron Odt39%Part D≥130 patients+ 8 more classes in this area
Respiratory
3.7%Corticosteroid3.7%Budesonide Dr55%Budesonide Ec45%Part D<11 patientsBlood & clotting
2.3%Solutions for parenteral nutrition2.3%Peg 3350-Electrolyte100%Part D≥31 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Josep M. Llovet
Institució Catalana de Recerca i Estudis Avançats
Joseph J.�Y. Sung
Nanyang Technological University
Neeraj Bhala
The Royal Melbourne Hospital
Jordi Bruix
Hospital Clínic de Barcelona
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”